You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 262 No. 17, November 3, 1989 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Toward Optimal Laboratory Use
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Routine Use of the Prothrombin and Partial Thromboplastin Times

Stephen B. Erban, MD; Judith L. Kinman, MA; J. Sanford Schwartz, MD

JAMA. 1989;262(17):2428-2432.


Abstract

The prothrombin time (PT) and activated partial thromboplastin time (APTT) tests are often routinely ordered for hospitalized patients. Ordering patterns and clinical indications for the PT and APTT tests on the medical service at a teaching hospital were studied. Eighty-one percent of all patients admitted to the medical service had a PT and APTT test ordered. When compared with a modified version of guidelines for the use of the PT and APTT tests recently developed by the Medical Necessity Project of the Blue Cross and Blue Shield Associations of America and endorsed by the American College of Physicians, at least 70% of these tests were not clinically indicated. Many of the unindicated tests were ordered prior to invasive procedures or, apparently, out of habit. These inappropriate PT and APTT tests cost at least $60 948 per year for the medical service. Based on these findings, we suggest methods of reducing the inappropriate use of the PT and APTT tests.

(JAMA. 1989;262:2428-2432)



Author Affiliations

From the Section of General Internal Medicine, Department of Medicine (Drs Erban and Schwartz), Clinical Epidemiology Unit (Ms Kinman and Dr Schwartz), and Leonard Davis Institute of Health Economics (Dr Schwartz), University of Pennsylvania, Philadelphia. Dr Erban is now with the Division of General Medicine and Primary Care, University of Massachusetts Medical Center, Worcester.


Footnotes

Reprint requests to Division of General Medicine and Primary Care, S7-715, University of Massachusetts Medical Center, 55 Lake Ave N, Worcester, MA 01655 (Dr Erban).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Coagulation Concepts Update
O'Connor et al.
Am. J. Roentgenol. 2009;193:1656-1664.
ABSTRACT | FULL TEXT  

Screening for the Risk for Bleeding or Thrombosis
Eckman et al.
ANN INTERN MED 2003;138:W-15-W-24.
ABSTRACT | FULL TEXT  

Do We Know What Inappropriate Laboratory Utilization Is?: A Systematic Review of Laboratory Clinical Audits
van Walraven and Naylor
JAMA 1998;280:550-558.
ABSTRACT | FULL TEXT  

Controlling the Hemorrhage of Routine Coagulation Tests
Fox
JAMA 1990;263:2749-2750.
ABSTRACT  

Anesthesiology
Roizen
JAMA 1990;263:2625-2627.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.